Sedation is the administration of drugs to reduce irritability or agitation, commonly used before or during surgical procedures to relax patients. It accounts for a significant share of perioperative care. According to World Health Organization reports, over 300 million surgical procedures are performed globally each year. Sedation therapeutics include benzodiazepines, propofol, and dexmedetomidine, with many newer agents under clinical development. The growing focus on patient safety, minimal side effects, and faster recovery is driving innovation in the pipeline. Sedation drug pipeline analysis by Expert Market Research highlights a robust pipeline with several novel candidates in clinical trials, indicating strong growth potential in the coming years.
Major companies involved in the sedation pipeline analysis include Melt Pharmaceuticals and MedTrials Incorporated, and others.
Leading drugs currently in the pipeline include MELT-300, Propofol, and others.
The rising ICU admissions, increasing volume of surgical procedures, and innovations in safer, faster-acting sedatives are key factors that are positively influencing the sedation pipeline landscape.
The Sedation Pipeline Analysis Report by Expert Market Research gives comprehensive insights into sedation therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for sedation. The sedation report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The sedation pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with sedation treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to sedation.
Sedation is a medically induced, controlled state of calm or unconsciousness used to reduce anxiety, discomfort, or pain during diagnostic or surgical procedures. It occurs through the administration of sedative drugs that act on the central nervous system, typically via intravenous or inhalation routes, resulting in a decreased level of awareness and responsiveness in the patient.
Sedation involves the use of agents such as benzodiazepines, propofol, or dexmedetomidine to manage patient anxiety, discomfort, or pain during medical procedures or intensive care stays. In July 2020, PAION AG announced the United States Food and Drug Administration approval of Remimazolam (Byfavo™) for procedural sedation in adults, highlighting its rapid onset and offset profile and favorable cardio-respiratory safety.
The global rise in surgical and diagnostic procedures continues to drive demand for effective sedation drugs. According to the World Health Organization, over 300 million surgeries are performed annually. A 2023 bibliometric study identified 3,154 publications on gastrointestinal endoscopy sedation from 2001-2022, with the United States leading in research output. Conscious sedation, colonoscopy, and midazolam remain key focus areas. These insights highlight ongoing advancements in sedation drug development.
This section of the report covers the analysis of sedation drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total sedation clinical trials at 35.42%. It is followed by phase III at 33.33%, phase II at 18.75%, phase I at 7.29%, and early phase I at 5.21%. This strong distribution in later phases indicates significant clinical progress. It reflects growing confidence in sedation therapies, potentially accelerating market approvals and improving treatment accessibility, safety, and efficacy.
The drug molecule categories covered under the sedation pipeline analysis include small molecules, peptides, monoclonal antibodies, natural products or derivatives, prodrugs, and others. The sedation report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for sedation.
Gamma-aminobutyric acid-A (GABAA) receptor modulators remain a key drug class in the sedation market. Ciprofol, a novel and highly selective GABAA receptor potentiator, is under clinical evaluation for sedation in mechanically ventilated patients in intensive care units. Its favorable pharmacokinetic profile and reduced adverse effects compared to propofol position it as a promising alternative.
The EMR report for the sedation pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed sedation therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in sedation clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for sedation. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of sedation drug candidates.
MELT-300 is currently being evaluated in a Phase III study sponsored by Melt Pharmaceuticals. This fast-dissolving sublingual tablet, combining 3 mg midazolam and 50 mg ketamine, targets opioid- and needle-free procedural sedation. The study aims to assess its efficacy and safety in adults undergoing cataract extraction with lens replacement, compared to placebo and sublingual midazolam.
Propofol is in a Phase II/III trial, where the drug candidate is being evaluated for its effects on spontaneous breathing in ICU patients with acute respiratory distress syndrome (ARDS). The study, sponsored by Guy's and St Thomas' NHS Foundation Trust, is examining how this inhaled volatile sedative, compared to intravenous Propofol, influences lung function and breathing drive during mechanical ventilation.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Sedation Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for sedation. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into sedation collaborations, regulatory environments, and potential growth opportunities.
Global Sedation in ICU Setting Market Report
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share